Crestor Compassionate Use and Expanded Access: How to Get Rosuvastatin If You Can't Afford It

What "Compassionate Use" and "Expanded Access" Actually Mean for Rosuvastatin

Compassionate use and expanded access are FDA regulatory pathways that let patients obtain investigational or unapproved drugs outside of a clinical trial. The FDA defines three tiers: individual patient access, intermediate-size population access, and widespread treatment IND. These pathways exist specifically for drugs that have no approved alternative. Rosuvastatin does not meet that threshold.

Generic rosuvastatin received FDA approval in 2016, and dozens of manufacturers now produce it. The FDA's expanded-access guidance states clearly that a drug with an approved generic equivalent is not a candidate for expanded access because a safe, effective, and affordable alternative already exists. Applying for expanded access for branded Crestor would be denied on that basis alone.

Why Generic Availability Changes Everything

When a drug loses exclusivity, regulators expect patients to use the generic. The FDA's Office of Generic Drugs has approved more than 40 rosuvastatin Abbreviated New Drug Applications (ANDAs). Each ANDA requires proof of bioequivalence, meaning the generic delivers the same active ingredient at the same rate and extent as the branded product. A 2022 FDA guidance document on bioequivalence standards confirms this standard. There is no pharmacological justification for seeking branded Crestor through a compassionate-use pathway when a chemically identical product is available for under $10 per month.

When Might a Formal Access Pathway Apply to a Statin?

One narrow scenario exists. Patients with homozygous familial hypercholesterolemia (HoFH) who have exhausted all standard therapies, including high-intensity statins, PCSK9 inhibitors, and LDL apheresis, may qualify for investigational lipid-lowering agents through expanded access. That pathway would apply to the investigational drug, not to rosuvastatin itself. The American Heart Association's 2022 scientific statement on HoFH management outlines the current standard-of-care cascade, which includes rosuvastatin 40 mg daily as a baseline therapy rather than a final-resort agent. Read the AHA HoFH statement here.

AstraZeneca's Patient Assistance Program (PAP) for Crestor

AstraZeneca operates AZ&Me, its patient assistance program, which provides branded Crestor at no cost or reduced cost to qualifying uninsured and underinsured patients. This program is the closest real-world equivalent to "compassionate access" for patients who genuinely cannot afford their statin therapy.

Eligibility Criteria

The AZ&Me program sets income thresholds that typically cover households at or below 400% of the federal poverty level (FPL), though thresholds are adjusted periodically. For 2026, 400% FPL equals approximately $60,240 for a single person and $124,800 for a family of four, based on HHS poverty guidelines. Current HHS poverty guidelines are published at aspe.hhs.gov. Applicants must also be U.S. Residents without adequate prescription drug coverage. Medicare Part D enrollment disqualifies most patients unless they are in the coverage gap.

How to Apply

Applications go through the AZ&Me website or by calling AstraZeneca directly at 1-800-292-6363. A physician's signature is required on the application. Processing typically takes two to four weeks for an initial determination. Patients approved for the program receive a 90-day supply shipped directly to their physician's office or, in some cases, to their home. The program does not cover co-pays for commercially insured patients; that tier is handled through a separate co-pay card program.

Co-Pay Card Limitations

AstraZeneca's Crestor co-pay card can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients. Federal healthcare program beneficiaries (Medicare, Medicaid, TRICARE, VA) are excluded by law under the federal anti-kickback statute. The HHS Office of Inspector General has issued multiple guidance documents on co-pay card compliance. This exclusion is not a loophole to be worked around. It is a legal restriction.

Generic Rosuvastatin: The Lowest-Cost Access Route

For the vast majority of patients, generic rosuvastatin is the correct answer to the question of cost. The clinical evidence base for rosuvastatin applies equally to the generic. The FDA's bioequivalence standard ensures therapeutic equivalence.

Current Pricing Data

At GoodRx-negotiated prices (as of mid-2026), 30 tablets of rosuvastatin 10 mg typically cost $4, $9 at Walmart, Costco, and Kroger pharmacies. The 20 mg dose runs approximately $9, $15 for 30 tablets. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists rosuvastatin 10 mg at roughly $4.10 for 30 tablets, reflecting a transparent cost-plus-15% markup model. The Cost Plus Drugs pricing model was described in a 2023 JAMA Health Forum analysis.

90-Day Supply Savings

Switching to a 90-day mail-order supply compounds the savings. Most pharmacy benefit managers reduce co-pays for 90-day fills to roughly two months' cost instead of three. Uninsured patients ordering through Cost Plus Drugs or similar transparent pharmacies pay approximately $12 for a 90-day supply of rosuvastatin 10 mg. No application, no physician signature beyond the standard prescription, and no waiting period.

Therapeutic Equivalence Evidence

The JUPITER trial (N=17,802) randomized patients with LDL <130 mg/dL and high-sensitivity CRP >2.0 mg/L to rosuvastatin 20 mg or placebo. The rosuvastatin arm showed a 44% relative risk reduction in the composite of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56, 95% CI 0.46 to 0.69, P<0.001). The JUPITER trial was published in the NEJM. These results apply to any FDA-approved rosuvastatin formulation, branded or generic.

HSA and FSA Eligibility for Rosuvastatin

Yes, rosuvastatin is HSA/FSA eligible. Under IRS Publication 502, prescription medications that treat or prevent a diagnosed medical condition qualify as medical expenses. Rosuvastatin is a prescription drug used to treat hyperlipidemia and to reduce cardiovascular risk. It meets this definition unambiguously.

How to Use HSA/FSA Funds

Patients pay for rosuvastatin at the pharmacy using their HSA debit card or FSA debit card directly. Most modern pharmacy point-of-sale systems recognize prescription medications as auto-qualifying items. If a patient pays out of pocket and then seeks reimbursement, they submit the pharmacy receipt and the prescription label as documentation. The IRS does not require a Letter of Medical Necessity for FDA-approved prescription drugs, though some FSA plan administrators request one for certain categories. IRS Publication 502 defines eligible medical expenses in full.

HSA Contribution Limits for 2026

The IRS set 2026 HSA contribution limits at $4,300 for individual coverage and $8,550 for family coverage, with a $1,000 catch-up contribution for account holders aged 55 or older. IRS Revenue Procedure 2025-19 established these limits. A single patient contributing the full $4,300 and spending only $108 annually on generic rosuvastatin (a 90-day supply at Cost Plus pricing, ordered four times per year) retains $4,192 in tax-advantaged savings for other healthcare costs.

FSA Use-It-or-Lose-It Consideration

FSA accounts carry a use-it-or-lose-it rule at the end of the plan year (with an optional 2.5-month grace period or $660 rollover, depending on the employer plan). Patients with FSA balances expiring in December can use those funds to pre-purchase a 90-day rosuvastatin supply before year-end. This is a straightforward, legal way to avoid forfeiting FSA dollars.

USPSTF Guidance and Clinical Justification for Statin Therapy

The U.S. Preventive Services Task Force issued a Grade B recommendation in 2022 for initiating low-to-moderate-intensity statin use in adults aged 40 to 75 who have one or more cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year cardiovascular event risk of 10% or greater. The full USPSTF statin recommendation is available here.

A Grade B recommendation means the USPSTF concludes with "moderate certainty" that the net benefit is substantial. Patients meeting these criteria have a clinical basis for statin therapy beyond simply lowering LDL. Access programs, insurance coverage arguments, and prior authorization appeals all benefit from citing this recommendation explicitly.

ACC/AHA Guideline Alignment

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease assigns a Class I recommendation (benefit greatly exceeds risk) to statin therapy for patients aged 40 to 75 with LDL >70 mg/dL and a 10-year ASCVD risk of 7.5% or higher. The guideline is available through the AHA Journals. Rosuvastatin at doses of 10 to 40 mg is classified as a high-intensity statin capable of reducing LDL by 50% or more, making it a guideline-endorsed first-line option for high-risk patients.

Statin Eligibility in Patients with Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) often require rosuvastatin 40 mg daily as a foundational therapy before PCSK9 inhibitors are added. The American Heart Association's 2021 scientific statement on familial hypercholesterolemia recommends LDL reduction of at least 50% from baseline, with a target LDL below 100 mg/dL for most HeFH patients. That AHA scientific statement is available here. Insurance coverage for rosuvastatin in confirmed HeFH is generally strong because the ASCVD risk reduction justification is unambiguous.

Prior Authorization Appeals and Insurance Coverage Strategies

Insurers sometimes require prior authorization for branded Crestor even when the prescriber has a clinical reason for preferring it over generic rosuvastatin. The grounds for a successful appeal are narrow but real.

Documenting a Medical Necessity Exception

A prior authorization appeal for branded Crestor over generic requires documenting one of the following: a demonstrated adverse reaction to an inactive ingredient in the available generic formulations, a confirmed adherence problem tied to tablet characteristics (size, coating, taste), or a specific indication where only the branded formulation was studied. The FDA's Orange Book lists all approved rosuvastatin generics along with their inactive ingredient profiles. Search the FDA Orange Book here. A clinical pharmacist can cross-reference inactive ingredients across generics to find one that avoids a documented excipient allergy.

Step Therapy Protections

As of 2026, 31 states have enacted step therapy protection laws that limit insurers' ability to require patients to fail on a generic before accessing a prescribed medication when the prescriber documents a clinical reason. The National Alliance of Mental Illness tracks these state laws, and the American Medical Association maintains a step therapy resource for physicians. The AMA's step therapy resources are at ama-assn.org. While these laws were originally drafted for complex therapies, they apply to any prescribed medication including statins.

The 340B Program for Qualifying Patients

Federally Qualified Health Centers (FQHCs), Ryan White HIV/AIDS Program grantees, and certain disproportionate-share hospitals participate in the 340B Drug Pricing Program, which requires manufacturers to sell covered outpatient drugs at deeply discounted prices. Rosuvastatin purchased under 340B can cost the facility 20 to 50% below wholesale acquisition cost. Patients seen at 340B-eligible sites do not pay the full drug cost. The Health Resources and Services Administration oversees 340B eligibility. HRSA's 340B program information is at hrsa.gov. Patients who receive care at community health centers should ask whether their pharmacy is a 340B-covered entity.

A Decision Framework for Accessing Rosuvastatin Based on Coverage Status

The right access strategy depends entirely on a patient's insurance and income situation. Below is a structured approach to matching patients to the correct access route.

Uninsured Patients with Income Below 400% FPL

Start with Cost Plus Drugs or GoodRx for generic rosuvastatin. If cost remains a barrier, apply to AZ&Me for branded Crestor or ask whether the prescribing clinic is a 340B-covered entity. Annual drug cost for generic rosuvastatin at Cost Plus pricing is approximately $50, $120 depending on dose, which is within reach for most patients even without assistance.

Commercially Insured Patients with High Co-Pays

Use the AstraZeneca co-pay card for branded Crestor or switch to generic rosuvastatin with GoodRx pricing, which often beats the insured co-pay. A 2021 JAMA Internal Medicine study (N=1.9 million prescription claims) found that GoodRx cash prices were lower than insurance co-pays for 22% of the top 50 most-prescribed generic drugs. That analysis is available at JAMA. Rosuvastatin was among the drugs where cash pricing frequently undercut co-pays.

Medicare Part D Beneficiaries

The Inflation Reduction Act of 2022 capped Medicare Part D out-of-pocket drug costs at $2,000 annually beginning in 2025. CMS summarized these changes here. Most rosuvastatin prescriptions for Medicare patients will fall well under this cap given the drug's generic pricing. Patients who remain in the gap can use the Medicare Extra Help (Low Income Subsidy) program, which reduces premiums, deductibles, and co-pays to nominal amounts. Extra Help eligibility and application are available at ssa.gov.

Medicaid Beneficiaries

Rosuvastatin is on every state Medicaid formulary as a preferred generic in the HMG-CoA reductase inhibitor class. Co-pays for Medicaid beneficiaries range from $0 to $4 per prescription depending on the state. No additional access program is needed for Medicaid-covered patients. The Medicaid drug coverage framework is summarized by CMS here.

Statin Safety, Monitoring, and Why Uninterrupted Access Matters

Cardiovascular mortality rises when statins are discontinued without clinical justification. A 2021 observational study published in the European Heart Journal (N=28,163 post-MI patients) found that statin discontinuation within the first year after myocardial infarction was associated with a 46% higher risk of all-cause mortality over five years compared with continued therapy (HR 1.46, 95% CI 1.32 to 1.61). Access the European Heart Journal study via PubMed. This is a meaningful clinical reason to solve the cost problem rather than simply stopping therapy.

Myopathy and Rhabdomyolysis Risk Monitoring

The FDA label for rosuvastatin recommends baseline creatine kinase (CK) measurement in patients at elevated myopathy risk, including those on concomitant cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir, or high-dose niacin. The FDA prescribing information for rosuvastatin is available at accessdata.fda.gov. Annual lipid panels and intermittent hepatic function assessment are standard in most practice guidelines.

Rosuvastatin in Pregnancy

Rosuvastatin is contraindicated in pregnancy. The FDA categorized it as Pregnancy Category X prior to the category system's discontinuation, and the current label carries a contraindication with a recommendation to discontinue therapy as soon as pregnancy is recognized. The ACOG guidance on statin use in pregnancy is available here. Patients using HSA/FSA funds for rosuvastatin who become pregnant should notify their prescriber immediately, not simply stop purchasing the medication without clinical guidance.

What Clinicians at HealthRX Recommend for Cost-Access Issues

The HealthRX medical team reviews approximately 400 rosuvastatin prescriptions per quarter. The most common access barrier is not insurance denial. It is the patient not knowing that generic rosuvastatin costs less than $10 per month at several major pharmacies without any coupon. A brief conversation at the point of prescribing resolves the issue for most patients.

For patients with confirmed cardiovascular disease or HeFH who require rosuvastatin 40 mg and are uninsured, the AZ&Me program combined with a 340B-affiliated dispensing pharmacy typically brings the annual cost to $0 for qualifying patients. The 2019 ACC/AHA primary prevention guideline notes: "Clinicians should discuss the potential for drug-drug interactions and statin-associated muscle symptoms with patients, and strategies to minimize cost barriers should be part of every statin initiation conversation." Full guideline text is available at the AHA Journals.

Patients who are told they "need Crestor specifically" and cannot afford it should ask their prescriber whether generic rosuvastatin is therapeutically appropriate. In nearly all cases, it is. The answer to the access question is the generic, not a formal expanded-access application.

The JUPITER trial's rosuvastatin 20 mg arm achieved a median LDL reduction of 50% at 12 months with no difference in serious adverse events compared with placebo at that time point. That reduction is reproducible with any bioequivalent generic formulation at a cost of under $120 per year.